These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36282671)

  • 1. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
    Alomari M; Kunacheewa C; Manasanch EE
    Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
    Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
    Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
    Guo P; Wang Y; He H; Chen D; Liu J; Qiang W; Lu J; Liang Y; Du J
    Clin Exp Immunol; 2024 Aug; 217(3):221-232. PubMed ID: 38743453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
    Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
    Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble B-cell maturation antigen in multiple myeloma.
    Costa BA; Ortiz RJ; Lesokhin AM; Richter J
    Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis].
    Zheng LL; Li B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1108-1112. PubMed ID: 37551484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS.
    Shen X; Dong X; Shi J; Chen H; Lan Y; Lim AC; Xie F; Ang A; Kratzer A; Rock DA; Rock BM
    Clin Chem; 2024 Jan; 70(1):339-349. PubMed ID: 38175591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
    Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
    Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
    Visram A; Soof C; Rajkumar SV; Kumar SK; Bujarski S; Spektor TM; Kyle RA; Berenson JR; Dispenzieri A
    Blood Cancer J; 2021 Jun; 11(6):120. PubMed ID: 34168119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
    Jew S; Chang T; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Spektor TM; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Berenson JR
    Br J Haematol; 2021 Jan; 192(2):272-280. PubMed ID: 32441777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
    Bujarski S; Sutanto C; Spektor TM; To J; Swift RA; Green T; Eades BR; Emamy-Sadr M; Souther E; Berenson JR
    Hematol Oncol; 2022 Apr; 40(2):243-248. PubMed ID: 34982491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
    Laurent SA; Hoffmann FS; Kuhn PH; Cheng Q; Chu Y; Schmidt-Supprian M; Hauck SM; Schuh E; Krumbholz M; Rübsamen H; Wanngren J; Khademi M; Olsson T; Alexander T; Hiepe F; Pfister HW; Weber F; Jenne D; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
    Nat Commun; 2015 Jun; 6():7333. PubMed ID: 26065893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
    Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
    Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.
    Maglione PJ; Ko HM; Tokuyama M; Gyimesi G; Soof C; Li M; Sanchez E; Chen H; Radigan L; Berenson J; Cunningham-Rundles C
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):283-291.e1. PubMed ID: 31430592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.